Advertisement
Advertisement
May 10, 2015
CE Mark Approved for Surefire Medical's Precision Infusion System for Embolization Procedures
May 8, 2015—Surefire Medical, Inc. announced European CE Mark approval for the company’s Precision targeted delivery infusion system for direct-to-tumor embolization procedures.
According to the company, the new-generation Surefire Precision device offers improved trackability and provides greater drug penetration into tumors. Surefire infusion systems are used primarily in treating inoperable liver cancers, although clinical trials are under way for additional medical conditions.
The company noted that primary hepatocellular cancer accounts for 83% of total liver cancer incidence. Liver cancer is the third most common cause of cancer deaths worldwide, with 2.2 million cases. With approximately 80% of liver cancers being inoperable, most patients today are treated with a minimally invasive embolization procedure performed by an interventional radiologist.
Advertisement
Advertisement
